Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Study of Elvitegravir/Ritonavir With Other Antiretrovirals in HIV-1 Infection
2007-004736-23Phase 2
- Sponsor
- Gilead Sciences
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elvitegravir in Human immunodeficiency virus infection type 1, sponsored by Gilead Sciences. Primary endpoint: Incidence of study drug related, treatment-emergent adverse events.
02
Drugs
elvitegravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2007-004736-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004736-23.